NIKKEI 225
28,903.25+19.12(+0.07%)HANG SENG
28,727.73+417.97(+1.48%)CRUDE OIL
73.08+0.02(+0.03%)
NOVARTIS AG NOVARTIS ORD SHS (0QLR.IL)
| Previous close | 86.00 |
| Open | 86.02 |
| Bid | 84.00 x N/A |
| Ask | 88.00 x N/A |
| Day's range | 85.42 - 86.16 |
| 52-week range | 24.00 - 308.00 |
| Volume | 313,277 |
| Avg. volume | 668,533 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline
All children (100%) treated presymptomatically in the SPR1NT two-copy cohort survived without respiratory or nutritional support, and sat independently for ≥30 seconds, most (11/14) within the WHO window of expected normal development The majority of children (82%) treated in STR1VE-EU achieved developmental motor milestones not observed in the natural history of SMA Type 1, including patients with more severe disease More than 1,200 patients have now been treated with Zolgensma globally across
- Globe Newswire
Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria1 – a key risk predictor in kidney disease progression2Iptacopan also showed a trend toward stabilization of kidney function1; Phase III clinical trial APPLAUSE is underwayThere are no currently approved treatments for IgAN – a rare and often progressive kidney disease that mainly affects young adults and can progress to kidney failure3-7Iptacopan is in
- Globe Newswire
Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
Tabrecta® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta achieved 65.6% overall response rate (ORR) in first-line and 51.6% in second-line settings in new expansion cohort analysis of additional patients1,2 Patient-reported outcomes on quality-of-life symptoms were also presented3 Tabrecta is the first therapy approved by the FDA to specifically target metastat
